A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy

We present 7 years of clinical experience with single-agent pembrolizumab immune checkpoint inhibitor immunotherapy in non-small cell lung cancers (NSCLC) from four UK cancer centres. This multi-institutional retrospective cohort study included 226 metastatic NSCLC patients. Outcomes were number and severity of immune-related adverse events (irAEs), median progression-free survival (mPFS) and median overall survival (mOS).Within our cohort, 119/226 (53%) patients developed irAEs. Of these, 54/119 (45%) experienced irAEs affecting two or more organ systems.

Source: Clinical Oncology - January 15, 2024 Category: Radiology Authors: A. Lerner, A.J.X. Lee, H. Yan, J. Van Griethuysen, A.D. Bartlett, M. Veli, Y. Jiang, M. Luong, N. Naban, C. Kane, J. Conibear, D. Papadatos-Pastos, T. Ahmad, D. Chao, G. Anand, U.S. Asghar Tags: Original Article Source Type: research